Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review.
COVID-19
Vaccine
effectiveness
older adults
waning
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
30 11 2022
30 11 2022
Historique:
pubmed:
5
3
2022
medline:
15
6
2022
entrez:
4
3
2022
Statut:
ppublish
Résumé
The U.S. Centers for Disease Control and Prevention (CDC) and other health agencies have recently recommended a booster dose of COVID-19 vaccines for specific vulnerable groups including adults 65 years and older. There is limited evidence whether vaccine effectiveness (VE) in older adults decreases over time, especially against severe COVID-19. We performed a rapid review of published studies available through 4 November 2021 that provide effectiveness data on messenger RNA (mRNA) vaccines approved/licensed in the United States and identified eight eligible studies which evaluated VE in older adults. There is evidence of a decline in VE against both severe acute respiratory syndrome coronavirus 2 infection and severe COVID-19 in older adults among studies which analyzed data up to July-October 2021. Our findings suggest that VE diminishes in older adults, which supports the current recommendation for a booster dose in this population.
Identifiants
pubmed: 35240940
doi: 10.1080/21645515.2022.2045857
pmc: PMC9196671
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Messenger
0
Vaccines, Synthetic
0
mRNA Vaccines
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2045857Références
MMWR Morb Mortal Wkly Rep. 2021 May 07;70(18):674-679
pubmed: 33956782
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
JAMA Netw Open. 2021 Oct 1;4(10):e2128391
pubmed: 34613401
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
Nat Rev Genet. 2021 Dec;22(12):757-773
pubmed: 34535792
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Science. 2022 Jan 21;375(6578):331-336
pubmed: 34735261
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1167-1169
pubmed: 34437521
Clin Infect Dis. 2022 Oct 3;75(Supplement_2):S159-S166
pubmed: 35675695
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166
pubmed: 34437519
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1088-1093
pubmed: 34383730
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
JAMA. 2021 Jul 21;:
pubmed: 34287620
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1294-1299
pubmed: 34529636
N Engl J Med. 2021 Oct 7;385(15):1355-1371
pubmed: 34496194